66 results on '"Taube, Christian"'
Search Results
2. Clinical Effects of compensatory Hyperinflation of the untreated Adjacent Lobe after Endoscopic Lung Volume Reduction with Valves
- Author
-
Wienker, J, Darwiche, Kaid, Wälscher, J, Winantea, Jane, Hagemann, M, Büscher, E, Singla, A, Taube, Christian, and Karpf-Wissel, Rüdiger
- Subjects
Medizin - Published
- 2023
3. Combined Lung- and Liver Transplantation for Patients with hepatopulmonary Syndrome and idiopathic Pulmonary Fibrosis - Case History
- Author
-
Höhn, A, Kleibrink, B, Kamler, Markus, Schmidt, H, and Taube, Christian
- Subjects
Medizin - Published
- 2023
4. The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort in comparison to patients on maintenance OCS therapy
- Author
-
Bal, Christina, Korn, Stephanie, Milger, Katrin, Skowasch, Dirk, Schulz, Christian, Zehetmayer, Sonja, Taube, Christian, Hamelmann, Eckard, Buhl, Roland, and Idzko, Marco
- Subjects
Medizin - Published
- 2023
5. Vacuolating Cytotoxin (VacA) reduces Airway Inflammation, Mucus Production and subepithelial Fibrosis in a therapeutic Model
- Author
-
Raspe, J, Schmitz, M, Übner, H, Westendorf, Astrid, Pastille, Eva, Cover, T, Müller, A, Taube, Christian, and Reuter, S
- Subjects
Medizin - Published
- 2023
6. Validation and Further Development of a contactless, camera-based Sensor System for the Detection of sleep-related Respiratory Disorders
- Author
-
Schöbel, Christoph, Eggert, T, Wildenauer, A, Dietz-Terjung, S, Große Sundrup, M, Weinreich, Gerhard, and Taube, Christian
- Subjects
Medizin - Published
- 2023
7. The Complexity of the Diagnosis of pulmonary cavernous Processes : A pneumological - rheumatological Case Report
- Author
-
Panagi, M, Taube, Christian, Darwiche, Kaid, Bonella, Francesco, Wessendorf, Thomas, Theegarten, Dirk, Kavruk, H, and Funke, Faustina
- Subjects
Medizin - Published
- 2023
8. Validation of a contactless radar-based Vital Sign Sensor against Ventilator-internal Therapy Data in out-of-hospital home mechanical Ventilation Patients to Predict Deterioration in Health Status
- Author
-
Schöbel, Christoph, Fischer, T, Wildenauer, A, Dietz-Terjung, S, and Taube, Christian
- Subjects
Medizin - Published
- 2023
9. Context Sensitive Links of 1 The Establishment of a flow cytometric Multi-parameter Analysis of BAL and its Validation by Correlation with the Findings of Routine Light Microscopy Diagnostics
- Author
-
Jehn, L, Bonella, Francesco, Raspel, J, Schmitz, M, Costabel, Ulrich, Taube, Christian, and Reuter, S
- Subjects
Medizin - Published
- 2023
10. The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort
- Author
-
Bal, Christina, Idzko, Marco, Milger, Katrin, Skowasch, Dirk, Schulz, Christian, Taube, Christian, Hamelmann, Eckard, Buhl, Roland, and Korn, Stephanie
- Subjects
Medizin - Abstract
Introduction: 718 of 2283 patients with severe asthma included in the real-life, long-term German Asthma Net (GAN) registry used anti-IL5(R) antibody therapy (mepolizumab, benralizumab, reslizumab), of which 343 had started therapy after registry inclusion (56±13 yrs., 55% female, 1.7% current smokers, mean BMI 27±5 kg/m², 4.6±4.6 exacerbations per year, ACQ score 2.9±1.4). Results: In comparison to baseline, patients on anti-IL5(R) therapy showed significantly less exacerbations (rate reduction (mean±SD) at year 1: -3.0±5.3, p
- Published
- 2023
11. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
- Author
-
Westhölter, Dirk, Raspe, Jonas, Uebner, Hendrik, Pipping, Johannes, Schmitz, Mona, Straßburg, Svenja, Sutharsan, Sivagurunathan, Welsner, Matthias, Taube, Christian, and Reuter, Sebastian
- Subjects
Immunology ,Medizin ,Immunology and Allergy - Abstract
IntroductionCystic fibrosis (CF), especially CF lung disease, is characterized by chronic infection, immune dysfunction including impairment of regulatory T cells (Tregs) and an exaggerated inflammatory response. CF transmembrane conductance regulator (CFTR) modulators have shown to improve clinical outcomes in people with CF (PwCF) with a wide range of CFTR mutations. However, it remains unclear whether CFTR modulator therapy also affects CF-associated inflammation. We aimed to examine the effect of elexacaftor/tezacaftor/ivacaftor therapy on lymphocyte subsets and systemic cytokines in PwCF.MethodsPeripheral blood mononuclear cells and plasma were collected before and at three and six months after the initiation of elexacaftor/tezacaftor/ivacaftor therapy; lymphocyte subsets and systemic cytokines were determined using flow cytometry.ResultsElexacaftor/tezacaftor/ivacaftor treatment was initiated in 77 PwCF and improved percent predicted FEV1 by 12.5 points (pConclusionTreatment with elexacaftor/tezacaftor/ivacaftor was associated with an increased percentage of Tregs, especially in PwCF clearing Pseudomonas aeruginosa infection. Targeting Treg homeostasis is a therapeutic option for PwCF with persistent Treg impairment.
- Published
- 2023
12. Development and progress in obstructive pulmonary diseases
- Author
-
Taube, Christian
- Subjects
Pulmonary and Respiratory Medicine ,Medizin - Published
- 2022
13. Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment
- Author
-
Kahnert, Kathrin, Andreas, Stefan, Kellerer, Christina, Lutter, Johanna I., Lucke, Tanja, Yildirim, Önder, Lehmann, Mareike, Seissler, Jochen, Behr, Jürgen, Frankenberger, Marion, Bals, Robert, Watz, Henrik, Welte, Tobias, Trudzinski, Franziska C., Vogelmeier, Claus F., Alter, Peter, Jörres, Rudolf A., Bahmer, Thomas, Bewig, Burkhard, Ewert, Ralf, Stubbe, Beate, Ficker, Joachim H., Grohé, Christian, Held, Matthias, Henke, Markus, Herth, Felix, Kirsten, Anne-Marie, Koczulla, Rembert, Kronsbein, Juliane, Kropf-Sanchen, Cornelia, Herzmann, Christian, Pfeifer, Michael, Randerath, Winfried J., Seeger, Werner, Studnicka, Michael, Taube, Christian, Timmermann, Hartmut, Schmeck, Bernd, Vogelmeier, Claus, and Wirtz, Hubert
- Subjects
Male ,Epidemiology ,Science ,Vital Capacity ,Medizin ,Article ,Body Mass Index ,Cohort Studies ,Pulmonary Disease, Chronic Obstructive ,Sex Factors ,Forced Expiratory Volume ,Diabetes Mellitus ,Humans ,Hypoglycemic Agents ,Lung ,Aged ,Multidisciplinary ,Smoking ,Age Factors ,Middle Aged ,respiratory system ,Metformin ,respiratory tract diseases ,Pulmonary Emphysema ,Pulmonary Diffusing Capacity ,Medicine ,Female ,Drug therapy - Abstract
We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin. Patients of GOLD grades 1–4 of the COSYCONET cohort with follow-up data of up to 4.5 y were included. The annual decline in lung function (FEV1, FVC) and CO diffusing capacity (KCO, TLCO) in %predicted at baseline was evaluated for associations with age, sex, BMI, pack-years, smoking status, baseline lung function, exacerbation risk, respiratory symptoms, cardiac disease, as well as metformin-containing therapy compared to patients without diabetes and metformin. Among 2741 patients, 1541 (mean age 64.4 y, 601 female) fulfilled the inclusion criteria. In the group with metformin treatment vs. non-diabetes the mean annual decline in KCO and TLCO was significantly lower (0.2 vs 2.3, 0.8 vs. 2.8%predicted, respectively; p 1 and FVC. These results were confirmed using multiple regression and propensity score analyses. Our findings demonstrate an association between the annual decline of lung diffusing capacity and the intake of metformin in patients with COPD consistent with the hypothesis of anti-aging effects of metformin as reflected in a surrogate marker of emphysema.
- Published
- 2022
14. Treatment with Helicobacter pylori-derived VacA attenuates allergic airway disease
- Author
-
Reuter, Sebastian, Raspe, Jonas, Uebner, Hendrik, Contoyannis, Alexandros, Pastille, Eva, Westendorf, Astrid M, Caso, Georgia C, Cover, Timothy L, Müller, Anne, Taube, Christian, University of Zurich, and Reuter, Sebastian
- Subjects
2403 Immunology ,Immunology ,10061 Institute of Molecular Cancer Research ,2723 Immunology and Allergy ,Medizin ,Immunology and Allergy ,570 Life sciences ,biology ,610 Medicine & health - Abstract
BackgroundAsthma is an incurable heterogeneous disease with variations in clinical and underlying immunological phenotype. New approaches could help to support existing therapy concepts. Neonatal infection of mice with Helicobacter pylori or administration of H. pylori-derived extracts or molecules after birth have been shown to prevent the development of allergic airway disease later in life. This study evaluated the potential therapeutic efficacy of H. pylori vacuolating cytotoxin A (VacA) in allergic airway inflammation and investigated the underlying immunological mechanisms for its actions.MethodsMurine models of allergic airway diseases, and murine and human in vitro models were used.ResultsIn both an acute model and a therapeutic house dust mite model of allergic airway disease, treatment with H. pylori-derived VacA reduced several asthma hallmarks, including airway hyperresponsiveness, inflammation and goblet cell metaplasia. Flow cytometry and ELISA analyses revealed induction of tolerogenic dendritic cells (DC) and FoxP3 positive regulatory T cells (Tregs), and a shift in the composition of allergen-specific immunoglobulins. Depletion of Tregs during treatment with VacA reversed treatment-mediated suppression of allergic airway disease. Human monocyte derived DCs (moDC) that were exposed to VacA induced Tregs in co-cultured naïve autologous T cells, replicating key observations made in vivo.ConclusionH. pylori-derived VacA suppressed allergic airway inflammation via induction of Tregs in both allergic airway disease models. These data suggest that the immunomodulatory activity of VacA could potentially be exploited for the prevention and treatment of allergic airway disease.
- Published
- 2023
15. Development of an inhaled anti-TSLP therapy for asthma
- Author
-
O'Byrne, Paul M., Panettieri, Reynold A., Taube, Christian, Brindicci, Caterina, Fleming, Margaret, and Altman, Pablo
- Subjects
Medizin - Published
- 2023
16. The molecular mechanisms of remodeling in asthma, COPD and IPF with a special emphasis on the complex role of Wnt5A
- Author
-
Singla, Abhinav, Reuter, Sebastian, Taube, Christian, Peters, Marcus, and Peters, Karin
- Subjects
Medizin - Abstract
Introduction Chronic inflammatory lung diseases are a common cause of suffering and death. Chronic obstructive pulmonary disease (COPD) is the reason for 6% of all deaths worldwide. A total of 262 million people are affected by asthma and 461,000 people died in 2019. Idiopathic pulmonary fibrosis (IPF) is diagnosed in 3 million people worldwide, with an onset over the age of 50 with a mean survival of only 24–30 months. These three diseases have in common that remodeling of the lung tissue takes place, which is responsible for an irreversible decline of lung function. Pathological lung remodeling is mediated by a complex interaction of different, often misguided, repair processes regulated by a variety of mediators. One group of these, as has recently become known, are the Wnt ligands. In addition to their well-characterized role in embryogenesis, this group of glycoproteins is also involved in immunological and structural repair processes. Depending on the combination of the Wnt ligand with its receptors and co-receptors, canonical and noncanonical signaling cascades can be induced.Wnt5A is a mediator that is described mainly in noncanonical Wnt signaling and has been shown to play an important role in different inflammatory diseases and malignancies. Objectives In this review, we summarize the literature available regarding the role of Wnt5A as an immune modulator and its role in the development of asthma, COPD and IPF. We will focus specifically on what is known about Wnt5A concerning its role in the remodeling processes involved in the chronification of the diseases. Conclusion Wnt5A has been shown to be involved in all three inflammatory lung diseases. Since the ligand affects both structural and immunological processes, it is an interesting target for the treatment of lung diseases whose pathology involves a restructuring of the lung tissue triggered in part by an inflammatory immune response.
- Published
- 2023
17. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort
- Author
-
von Siemens, Sarah Marietta, Perneczky, Robert, Waschki, Benjamin, Lutter, Johanna I, Welte, Tobias, Jörres, Rudolf A, Kahnert, Kathrin, group, COSYCONET study, Andreas, Stefan, Bals, Robert, Behr, Jürgen, Vogelmeier, Claus F, Bewig, Burkhard, Buhl, Roland, Ewert, Ralf, Stubbe, Beate, Gogol, Manfred, Grohé, Christian, Hauck, Rainer, Held, Matthias, Jany, Berthold, Henke, Markus, Herth, Felix, Höffken, Gerd, Katus, Hugo A, Kirsten, Anne-Marie, Watz, Henrik, Koczulla, Rembert, Kenn, Klaus, Kronsbein, Juliane, Kropf-Sanchen, Cornelia, Lange, Christoph, Kauffmann-Guerrero, Diego, Zabel, Peter, Pfeifer, Michael, Randerath, Winfried J, Seeger, Werner, Studnicka, Michael, Taube, Christian, Teschler, Helmut, Timmermann, Hartmut, Virchow, J Christian, Vogelmeier, Claus, Alter, Peter, Wagner, Ulrich, Wirtz, Hubert, Trudzinski, Franziska C, and Söhler, Sandra
- Subjects
Male ,medicine.medical_specialty ,epidemiology [Cognitive Dysfunction] ,psychology [Pulmonary Disease, Chronic Obstructive] ,Medizin ,Comorbidity ,Cohort Studies ,03 medical and health sciences ,FEV1/FVC ratio ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Cognition ,epidemiology [Pulmonary Disease, Chronic Obstructive] ,Surveys and Questionnaires ,medicine ,Dementia ,Humans ,COPD ,Cognitive Dysfunction ,ddc:610 ,Cognitive skill ,Path analysis (statistics) ,Aged ,lcsh:RC705-779 ,business.industry ,Research ,physiology [Cognition] ,diagnosis [Pulmonary Disease, Chronic Obstructive] ,lcsh:Diseases of the respiratory system ,Middle Aged ,medicine.disease ,Mental Status and Dementia Tests ,humanities ,Cross-Sectional Studies ,Cognitive impairment ,diagnosis [Cognitive Dysfunction] ,030228 respiratory system ,Cohort ,Physical therapy ,Female ,psychology [Cognitive Dysfunction] ,business ,030217 neurology & neurosurgery ,Cognitive load - Abstract
Alterations of cognitive functions have been described in COPD. Our study aimed to disentangle the relationship between the degree of cognitive function and COPD characteristics including quality of life (QoL).Data from 1969 COPD patients of the COSYCONET cohort (GOLD grades 1–4; 1216 male/ 753 female; mean (SD) age 64.9 ± 8.4 years) were analysed using regression and path analysis. The DemTect screening tool was used to measure cognitive function, and the St. George‘s respiratory questionnaire (SGRQ) to assess disease-specific QoL.DemTect scores were =60 years of age. For statistical reasons, we used the average of both algorithms independent of age in all subsequent analyses. The DemTect scores were associated with oxygen content, 6-min-walking distance (6-MWD), C-reactive protein (CRP), modified Medical Research Council dyspnoea scale (mMRC) and the SGRQ impact score. Conversely, the SGRQ impact score was independently associated with 6-MWD, FVC, mMRC and DemTect. These results were combined into a path analysis model to account for direct and indirect effects. The DemTect score had a small, but independent impact on QoL, irrespective of the inclusion of COPD-specific influencing factors or a diagnosis of cognitive impairment.We conclude that in patients with stable COPD lower oxygen content of blood as a measure of peripheral oxygen supply, lower exercise capacity in terms of 6-MWD, and higher CRP levels were associated with reduced cognitive capacity. Furthermore, a reduction in cognitive capacity was associated with reduced disease-specific quality of life. As a potential clinical implication of this work, we suggest to screen especially patients with low oxygen content and low 6-MWD for cognitive impairment.
- Published
- 2022
- Full Text
- View/download PDF
18. Helicobacter Pylori Derived Vacuolating Cytotoxin A (VacA) Modulates the Allergen Specific Interaction of Dendritic Cells with T Cells
- Author
-
Raspe, Jonas, Beckert, H., Cover, T. L., Müller, A., Taube, Christian, and Reuter, S.
- Subjects
Medizin ,ComputingMethodologies_GENERAL - Abstract
Poster-Abstract
- Published
- 2022
19. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
- Author
-
Drick, Nora, Milger, Katrin, Seeliger, Benjamin, Fuge, Jan, Korn, Stephanie, Buhl, Roland, Schuhmann, Maren, Herth, Felix, Kendziora, Benjamin, Behr, Juergen, Kneidinger, Nikolaus, Bergmann, Karl-Christian, Taube, Christian, Welte, Tobias, and Suhling, Hendrik
- Subjects
severe asthma ,benralizumab ,Medizin ,mepolizumab ,eosinophils ,reslizumab ,Original Research - Abstract
Background: Anti-IL-5 antibodies represent an established therapy for severe eosinophilic asthma (SEA), but some patients show inadequate response. The objective of this study was to assess the effects of a switch to anti-IL-5Rα therapy in patients with inadequate response to anti-IL-5 therapy. Methods: In this retrospective multi-centre, real-life study, we analysed all SEA patients switched from anti-IL-5 to anti-IL-5Rα therapy due to inadequate response or intolerability. Pulmonary function tests, blood gas analyses, asthma control tests (ACT) and oral corticos-teroid (OCS) usage were analysed and compared at three timepoints: baseline (BL, before anti-IL-5 therapy), timepoint 1 (T1, under anti-IL-5 therapy) and timepoint 2 (T2, under anti-IL-5Rα therapy). Results: Of 665 patients treated with anti-IL-5 antibodies, 70 were switched to anti-IL-5Rα and 60 were included in the analysis. Median treatment duration was 8 months [IQR 5; 15] for anti-IL-5 and 5 months [IQR 4; 6] for anti-IL-5Rα therapy. FEV₁ was 61% of predicted at BL [IQR 41; 74], 61% [IQR 43; 79] at T1 and 68% [IQR 49; 87] at T2 (pT₁₋T₂=0.011). ACT score was 10 [IQR 8; 13], 16 [IQR 10; 19] and 19 [IQR 14; 22], respectively (both p
- Published
- 2020
20. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET
- Author
-
Trudzinski, F.C., Jörres, R.A., Alter, P., Kahnert, K., Waschki, B., Herr, C., Kellerer, C., Omlor, A., Vogelmeier, C.F., Fähndrich, S., Watz, H., Welte, T., Jany, B., Söhler, S., Biertz, F., Herth, F., Kauczor, H.-U., Bals, R., Andreas, Stefan, Behr, Jürgen, Bewig, Burkhard, Buhl, Roland, Ewert, Ralf, Stubbe, Beate, Ficker, Joachim H., Gogol, Manfred, Grohé, Christian, Hauck, Rainer, Held, Matthias, Henke, Markus, Höffken, Gerd, Katus, Hugo A., Kirsten, Anne-Marie, Koczulla, Rembert, Kenn, Klaus, Kronsbein, Juliane, Kropf-Sanchen, Lange, Christoph, Zabel, Peter, Pfeifer, Michael, Randerath, Winfried J., Seeger, Werner, Studnicka, Michael, Taube, Christian, Teschler, Helmut, Timmermann, Hartmut, Virchow, J. Christian, Wagner, and Wirtz, Hubert
- Subjects
Adult ,Male ,medicine.medical_specialty ,Exacerbation ,Medizin ,lcsh:Medicine ,Severity of Illness Index ,Gastroenterology ,Article ,Pulmonary Disease, Chronic Obstructive ,03 medical and health sciences ,Medical research ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Signs and symptoms ,lcsh:Science ,Survival rate ,Aged ,Oxygen saturation (medicine) ,Aged, 80 and over ,Inflammation ,COPD ,Oxygenated Hemoglobin ,Multidisciplinary ,Proportional hazards model ,business.industry ,Hazard ratio ,lcsh:R ,Middle Aged ,Prognosis ,medicine.disease ,Comorbidity ,Survival Rate ,Risk factors ,030228 respiratory system ,Oxyhemoglobins ,Female ,lcsh:Q ,Blood Gas Analysis ,business ,Biomarkers - Abstract
We studied whether in patients with stable COPD blood gases (BG), especially oxygenated hemoglobin (OxyHem) as a novel biomarker confer information on disease burden and prognosis and how this adds to the information provided by the comorbidity pattern and systemic inflammation. Data from 2137 patients (GOLD grades 1–4) of the baseline dataset of the COSYCONET COPD cohort were used. The associations with dyspnea, exacerbation history, BODE-Index (cut-off ≤2) and all-cause mortality over 3 years of follow-up were determined by logistic and Cox regression analyses, with sex, age, BMI and pack years as covariates. Predictive values were evaluated by ROC curves. Capillary blood gases included SaO2, PaO2, PaCO2, pH, BE and the concentration of OxyHem [haemoglobin (Hb) x fractional SaO2, g/dL] as a simple-to-measure correlate of oxygen content. Inflammatory markers were WBC, CRP, IL-6 and -8, TNF-alpha and fibrinogen, and comorbidities comprised a broad panel including cardiac and metabolic disorders. Among BG, OxyHem was associated with dyspnoea, exacerbation history, BODE-Index and mortality. Among inflammatory markers and comorbidities, only WBC and heart failure were consistently related to all outcomes. ROC analyses indicated that OxyHem provided information of a magnitude comparable to that of WBC, with optimal cut-off values of 12.5 g/dL and 8000/µL, respectively. Regarding mortality, OxyHem also carried independent, additional information, showing a hazard ratio of 2.77 (95% CI: 1.85–4.15, p 8000/µL was 2.33 (95% CI: 1.60–3.39, p 2. It thus appears well suited for clinical use with minimal equipment, especially for GPs.
- Published
- 2020
21. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c
- Author
-
Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szépfalusi, Zsolt, Pohl, Wolfgang, Hötzenecker, Wolfram, Rosenkranz, Alexander, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Claus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink Wagner, Antje, Horak, Fritz, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Matricardi, Paolo M., Spertini, François, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Larent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Jürgen, O´Mahony, Liam, Knol, Edward, del Giacco, Stefano, Chivato, Tomás, Bousquet, Jean, Zuberbier, Torsten, Akdis, Cezmi, and Jutel, Marek
- Subjects
Titel ,SARS-CoV-2 ,Medizin ,Immunology and Allergy ,Omalizumab ,Benralizumab ,Dupilumab ,Reslizumab ,Covid-19 ,Telemedizin ,Mepolizumab - Published
- 2020
22. Expiratory filter sets substantially reduce exhaled small bioaerosol particles and potential COVID-19 virus load
- Author
-
Hautzel, H., Bartel, T., Darwiche, Kaid, Aigner, Clemens, Taube, Christian, and Herrmann, Ken
- Subjects
Medizin - Abstract
Poster-Abstract
- Published
- 2022
23. The pathological oral cavity as a preventable source of postoperative pneumonia in thoracic surgery : A prospective observational study
- Author
-
Ploenes, Till, Pollok, Arianne, Jöckel, Karl-Heinz, Kampe, Sandra, Darwiche, Kaid, Taube, Christian, Buer, Jan, and Aigner, Clemens
- Subjects
Medizinische Fakultät » Universitätsklinikum Essen » Institut für Medizinische Mikrobiologie ,Pulmonary and Respiratory Medicine ,Medizinische Fakultät » Universitätsklinikum Essen » Ruhrlandklinik Essen – Universitätsklinik ,periodontal disease ,Tooth Decay ,Medizin ,Early Recovery ,Oral Health ,Enhanced Recovery After Surgery (Eras) ,Caries ,Original Article ,ddc:610 ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Medizinische Informatik, Biometrie und Epidemiologie ,Complication - Abstract
Background: Pneumonia after thoracic surgery considerably contributes to perioperative morbidity and mortality. So far, the forced expiratory volume in one second and diffusing capacity of the lungs for carbon dioxide are the most common validated prognosticators to estimate individual risk. Beyond functional parameters, modifiable risk factors for respiratory complications like pneumonia are poorly investigated in a prospective way. Thus, we aimed to assess the impact of oral health status in patients undergoing thoracic surgery and its correlation to perioperative outcomes. Methods: A prospective observational study included adult patients undergoing elective thoracic surgery from October 2, 2018 to April 29, 2020. The day before surgery, patients were examined by a dentist. Oral health status (caries, periodontal disease, tooth loss, and regular dental visits) was correlated with perioperative outcomes. Results: During the study period, 230 consecutive patients were included. Oral health status was poor in the study population. Postoperative complications were associated with active caries [odds ratio (OR) 2.5, P
- Published
- 2022
24. ORMDL3 gene polymorphisms in patients with pulmonary alveolar proteinosis (PAP) and interstitial lung diseases (ILDs) : preliminary results
- Author
-
Bonella, Francesco, Hässig, D., Cabric, S., Waelscher, J., Boerner, E., Jehn, L., Taube, Christian, and Schedel, M.
- Subjects
Medizin ,ComputingMethodologies_GENERAL - Abstract
Poster-Abstract
- Published
- 2022
25. Corrigendum to 'The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control'
- Author
-
Korn, Stephanie, Milger, Katrin, Skowasch, Dirk, Timmermann, Hartmut, Taube, Christian, Idzko, Marco, Voß, Hans Werner, Holtdirk, Annette, Hamelmann, Eckard, and Buhl, Roland
- Subjects
Medizin - Abstract
The authors regret that Sanofi, one of the funders of the German Asthma Net, was omitted from the acknowledgements and funding section of the manuscript. The full disclosure should read: The GAN Severe Asthma Registry is supported by the German Asthma Net e.V., a German nonprofit society, and is funded by the German Ministry for Education and Research in the CHAMP consortium (BMBF, 01GL1742D); the GAN is also being funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, and Teva. The authors would like to apologise for any inconvenience caused.
- Published
- 2022
26. Sarkoidose
- Author
-
Wälscher, Julia, Wessendorf, Thomas, Darwiche, Kaid, Taube, Christian, and Bonella, Francesco
- Subjects
Pulmonary and Respiratory Medicine ,Medizin - Published
- 2022
27. Immune Checkpoint Inhibitor (ICI)-associated Pulmonary Manifestations (ICI-LM): Characterization of HRCT and BAL Findings
- Author
-
Jehn, B. L., Waelscher, J., Wessendorf, Thomas, Livingstone, Elisabeth, Zimmer, Lisa, Metzenmacher, M., Eberhardt, Wilfried, Theegarten, Dirk, Taube, Christian, and Bonella, Francesco
- Subjects
Medizin - Published
- 2022
28. Wave riding : 12 months of COVID-19 in a German tertiary care center
- Author
-
Fistera, David, Pabst, Dirk, Falk, Maximilian, Anastasiou, Olympia E., Goer, Stefan, Dolff, Sebastian, Konik, Margarethe, Herbstreit, Frank, Taube, Christian, Kill, Clemens, and Risse, Joachim
- Subjects
Medizin - Abstract
Einleitung Mit weit mehr als 1400 stationär behandelten COVID-19-Patienten ist die Universitätsmedizin Essen der größte COVID-19-Versorger der Region Rhein-Ruhr. Wir präsentieren die Daten unserer Patienten aus den ersten 12 Monaten der Pandemie und die hieraus entstandenen praktischen Konzepte. Methode Retrospektive Analyse aller 1396 stationären COVID-19-Patienten, die zwischen dem 1. März 2020 und 28. Februar 2021 versorgt wurden, im Hinblick auf Komorbiditäten, Überleben und Komplikationen im Verlauf. Es erfolgte ein Gruppenvergleich zwischen Patienten auf Normalstation und Überwachungs-/ Intensivstation. Ergebnisse Bei einer Gesamtmortalität von 19,8 % (277/1396) starben 10,6 % (93/877) der Patienten auf Normalstation und 35,5 % (184/519) der Patienten auf Intensiv- und Überwachungsstationen im klinischen Verlauf. Hierbei waren ein Alter über 60 Jahre, Adipositas, maschinelle Beatmung, NO-Therapie, ECMO-Therapie sowie akutes Nierenversagen und Apoplex im Therapieverlauf unabhängige Prädiktoren für Mortalität. Fazit Die Mortalität unseres Kollektivs auf Normal- bzw. Intensivstationen liegt im Rahmen international publizierter Daten. Sowohl die hohe Rate von Komplikationen bei schwerem Verlauf als auch die große Bedeutung einfacher Komorbiditäten kann eindrücklich gezeigt werden. Das mittlere Alter der Patienten ist mit 60 Jahren auf Normalstation und 63 Jahren auf Intensivstationen überraschend niedrig. Maximaler Patienten- und Personalschutz, eine rasche und effektive Teststrategie im Rahmen der primären Triage, standardisierte Abläufe von der Notaufnahme bis zur Intensivstation sowie eine dynamische tagesaktuelle Anpassung der Ressourcen können eine hohe Versorgungsqualität, auch während der Pandemie, sichern.
- Published
- 2022
29. Frequency and reasons for biologics switching in severe asthma
- Author
-
Gerstlauer, M., Seefeldt, M., Buhl, R., Hamelmann, E., Taube, Christian, Idzko, M., and Korn, S.
- Subjects
Medizin ,ComputingMethodologies_GENERAL - Abstract
Poster Abstract
- Published
- 2022
30. Influence of the early-life gut microbiota on the immune responses to an inhaled allergen
- Author
-
Borbet, Timothy C, Pawline, Miranda B, Zhang, Xiaozhou, Wipperman, Matthew F, Reuter, Sebastian, Maher, Timothy, Li, Jackie, Iizumi, Tadasu, Gao, Zhan, Daniele, Megan, Taube, Christian, Koralov, Sergei B, Müller, Anne, Blaser, Martin J, and University of Zurich
- Subjects
Immunology ,Pyroglyphidae ,10061 Institute of Molecular Cancer Research ,Immunity ,Medizin ,Amoxicillin ,610 Medicine & health ,Allergens ,Azithromycin ,Immunoglobulin E ,Anti-Bacterial Agents ,Gastrointestinal Microbiome ,Mice ,Th2 Cells ,Immunology and Allergy ,Animals ,Cytokines ,570 Life sciences ,biology - Abstract
Antibiotics, among the most used medications in children, affect gut microbiome communities and metabolic functions. These changes in microbiota structure can impact host immunity. We hypothesized that early-life microbiome alterations would lead to increased susceptibility to allergy and asthma. To test this, mouse pups between postnatal days 5-9 were orally exposed to water (control) or to therapeutic doses of azithromycin or amoxicillin. Later in life, these mice were sensitized and challenged with a model allergen, house dust mite (HDM), or saline. Mice with early-life azithromycin exposure that were challenged with HDM had increased IgE and IL-13 production by CD4
- Published
- 2022
- Full Text
- View/download PDF
31. S3-Leitlinie Allergieprävention
- Author
-
Kopp, Matthias V., Muche-Borowski, C., Abou-Dakn, M., Ahrens, B., Beyer, K., Blümchen, K., Bubel, P., Chaker, A., Cremer, M., Ensenauer, R., Gerstlauer, M., Gieler, U., Hübner, I.M., Horak, F., Klimek, L., Koletzko, B.V., Koletzko, S., Lau, S., Lob-Corzilius, T., Nemat, K., Peters, E.M.J., Pizzulli, A., Reese, I., Rolinck-Werninghaus, C., Rouw, E., Schaub, B., Schmidt, S., Steiß, J.O., Striegel, A.K., Szépfalusi, Z., Schlembach, D., Spindler, T., Taube, Christian, Trendelenburg, V., Treudler, R., Umpfenbach, U., Vogelberg, C., Wagenmann, M., Weißenborn, A., Werfel, T., Worm, M., Sitter, H., Hamelmann, Eckard, Hübner, Inga-Marie, Koletzko, Berthold V., Peters, Eva M.J., Steiß, Jens-Oliver, and Striegel, Anne Kathrin
- Subjects
Medizin - Abstract
Hintergrund: Die anhaltend hohe Prävalenz allergischer Erkrankungen in westlichen Industrienationen und die eingeschränkten Möglichkeiten einer kausalen Therapie machen eine evidenzbasierte Primärprävention notwendig. Methoden: Die Empfehlungen der in letzter Fassung 2014 veröffentlichten S3-Leitlinie Allergieprävention wurden auf der Basis einer aktuellen systematischen Literatursuche überarbeitet und konsentiert. Die Evidenzsuche erfolgte für den Zeitraum 06/2013 – 11/2020 in den elektronischen Datenbanken Cochrane und MEDLINE, sowie in den Referenzlisten von aktuellen Übersichtsarbeiten und durch Hinweise von Experten. Die aufgefundene Literatur wurde in zwei Filterprozessen zunächst nach Titel und Zusammenfassung und die verbliebenen Arbeiten im Volltext auf Relevanz hin überprüft. Die danach eingeschlossenen Studien wurden nach Evidenzgrade geordnet und die Studienqualität i.S. des Verzerrungspotenzials (niedrig/hoch) angegeben. Die überarbeiteten Empfehlungen wurden unter Beteiligung von Vertretern der relevanten Fachgesellschaften und (Selbsthilfe-)Organisationen formal abgestimmt und konsentiert (nominaler Gruppenprozess). Von 5.681 Treffern wurden 286 Studien eingeschlossen und bewertet. Ergebnisse: Einen wichtigen Stellenwert in der aktualisierten Leitlinie nehmen wieder Empfehlungen zur Ernährung der Mutter während der Schwangerschaft und Stillzeit sowie des Säuglings in den ersten Lebensmonaten ein: Dabei wurden viele der bisherigen Empfehlungen durch die aktuelle Datenlage bestätigt. Präzisiert wurde, dass für den Zeitraum der ersten 4 – 6 Monate nach Geburt nach Möglichkeit ausschließlich gestillt werden soll und auch mit Einführung von Beikost weitergestillt werden soll. Neu ist die Empfehlung, dass eine Zufütterung von kuhmilchbasierter Formulanahrung in den ersten Lebenstagen bei Stillwunsch der Mutter vermieden werden sollte. Ferner wurde festgestellt, dass die Evidenz für eine klare positive Empfehlung für hydrolysierte Säuglingsnahrung bei nicht gestillten Risikokindern aktuell nicht mehr ausreicht. Aktuell wird daher empfohlen zu prüfen, ob bis zur Einführung von Beikost eine Säuglingsanfangsnahrung mit in Studien zur Allergieprävention nachgewiesener Wirksamkeit verfügbar ist. Schließlich wurden auf Basis der EAACI-Leitlinie zur Prävention der Hühnereiallergie die Empfehlung ausgesprochen, durcherhitztes (zum Beispiel verbackenes oder hartgekochtes), aber nicht „rohes“ Hühnerei (auch kein Rührei) mit der Beikost einzuführen und regelmäßig weiter zu geben. Die Empfehlung zur Einführung von Erdnuss in der Beikost wurde für den deutschsprachigen Raum zurückhaltend formuliert: In Familien mit bereits bestehendem regelmäßigem Erdnusskonsum kann zur Prävention einer Erdnussallergie bei Säuglingen mit atopischer Dermatitis die regelmäßige Gabe von erdnusshaltigen Nahrungsmitteln in altersgerechter Form (zum Beispiel Erdnussbutter) mit der Beikost erwogen werden. Vor der Einführung muss insbesondere bei Säuglingen mit moderater bis schwerer AD eine klinisch relevante Erdnussallergie ausgeschlossen werden. Für eine allergiepräventive Wirksamkeit von Präbiotika oder Probiotika, Vitamin D oder anderen Vitaminen in Form von Präparaten fehlt weiterhin ausreichende Evidenz, sodass in der aktuellen Leitlinie erstmals Empfehlungen gegen deren Supplementierung verabschiedet wurden. Die Biodiversität spielt für die Entwicklung einer immunologischen Toleranz gegenüber Umwelt- und Nahrungsmittelallergenen eine wichtige Rolle: So gibt es deutliche Hinweise darauf, dass das Aufwachsen auf dem Bauernhof mit einem geringeren Risiko für die Entwicklung von Asthma und allergischen Erkrankungen assoziiert ist. Dies wird mit einer frühzeitigen unspezifischen Immunstimulation unter anderem durch die größere mikrobielle Biodiversität des Hausstaubs in diesem Lebensraum in Verbindung gebracht. Dieser Aspekt spiegelt sich auch in den Empfehlungen zur Tierhaltung wider, zu der eine differenzierte Stellungnahme erfolgte: In Familien ohne erkennbares erhöhtes Allergierisiko soll die Haustierhaltung mit Katzen oder Hunden nicht generell eingeschränkt werden. Familien mit erhöhtem Allergierisiko (d. h. Vater, Mutter oder Geschwisterkind sind von einer atopischen Erkrankung betroffen) oder bei Kindern mit bereits bestehender atopischer Dermatitis sollten eine Katze nicht neu anschaffen – im Gegensatz dazu sollte von einer Hundehaltung jedoch nicht abgeraten werden. Interventionen zur Reduktion der Exposition gegenüber Hausstaubmilbenallergenen im Haushalt, zum Beispiel die Verwendung milbenallergendichter Matratzenüberzüge („encasings“), sollten nicht mit dem Ziel einer primären Allergieprävention erfolgen. Kinder, die durch einen Kaiserschnitt geboren wurden, haben ein geringfügig erhöhtes Asthmarisiko – dies soll bei der Beratung zum Geburtsmodus außerhalb von Notfallsituationen berücksichtigt werden. Auch aktuelle Arbeiten stützen die Empfehlungen zu Luftschadstoffen: Die aktive und passive Exposition gegenüber Tabakrauch erhöhen das Allergierisiko und sind deshalb zu vermeiden. Die Exposition gegenüber Stickoxiden, Ozon und Feinstaub der Partikelgröße < 2,5 Mikrometer (PM 2,5) ist mit einem erhöhten Risiko, besonders für Asthma, verbunden. Daher sollte die Exposition gegenüber Emissionen gegenüber Stickoxiden, Ozon und Feinstaub (PM 2,5) gering gehalten werden. Die Autor/-innen dieser Leitlinie sprechen sich einhellig für den Erlass entsprechender Verordnungen zur Minimierung dieser Luftschadstoffe aus. Es gibt keine Belege, dass Impfungen das Allergierisiko erhöhen, umgekehrt aber Hinweise, dass Impfungen das Allergierisiko senken können. Alle Kinder, auch Risikokinder, sollen auch aus Gründen der Allergieprävention nach den aktuellen Empfehlungen der STIKO geimpft werden. Schlussfolgerung: Die Konsentierung von Empfehlungen in dieser Leitlinie beruht auf einer umfangreichen Evidenzgrundlage. Die Aktualisierung der Leitlinie ermöglicht evidenzbasierte und aktuelle Empfehlungen zur Prävention allergischer Erkrankungen.
- Published
- 2022
32. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort
- Author
-
Heaney, Liam G., Perez de Llano, Luis, Al-Ahmad, Mona, Backer, Vibeke, Busby, John, Canonica, Giorgio Walter, Christoff, George C., Cosio, Borja G., FitzGerald, J. Mark, Heffler, Enrico, Iwanaga, Takashi, Jackson, David J., Menzies-Gow, Andrew N., Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Pfeffer, Paul E., Popov, Todor A., Porsbjerg, Celeste M., Rhee, Chin Kook, Sadatsafavi, Mohsen, Tohda, Yuji, Wang, Eileen, Wechsler, Michael E., Alacqua, Marianna, Altraja, Alan, Bjermer, Leif, Björnsdóttir, Unnur S., Bourdin, Arnaud, Brusselle, Guy G., Buhl, Roland, Costello, Richard W., Hew, Mark, Koh, Mariko Siyue, Lehmann, Sverre, Lehtimäki, Lauri, Peters, Matthew, Taillé, Camille, Taube, Christian, Tran, Trung N., Zangrilli, James, Bulathsinhala, Lakmini, Carter, Victoria A., Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Kerkhof, Marjan, Murray, Ruth B., Price, Chris A., Price, David B., Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Epidemiology, Tampere University, Department of Respiratory medicine, Dermatology and Allergology, and Clinical Medicine
- Subjects
PROTOCOL ,Adult ,Male ,Asia ,[SDV]Life Sciences [q-bio] ,Medizin ,3121 Internal medicine ,Global Health ,Severity of Illness Index ,VALIDATION ,International Severe Asthma Registry ,MECHANISMS ,Cohort Studies ,Leukocyte Count ,Middle East ,Adrenal Cortex Hormones ,Eosinophilia ,Medicine and Health Sciences ,Prevalence ,Humans ,Anti-Asthmatic Agents ,Registries ,Age of Onset ,PREDICTORS ,ComputingMilieux_MISCELLANEOUS ,RECEPTOR ,BENRALIZUMAB ,Middle Aged ,Asthma ,Patient Care Management ,Respiratory Function Tests ,Eosinophils ,Europe ,Biological Variation, Population ,North America ,Female ,FENO - Abstract
Background: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. Research Question: What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables? Study Design and Methods: This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a predefined gradient eosinophilic algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional exhaled nitric oxide, nasal polyps, and adult-onset asthma. Demographic and clinical characteristics were defined at baseline (ie, 1 year before or closest to date of BEC). Results: One thousand seven hundred sixteen patients with prospective data were included; 83.8% were identified as most likely (grade 3), 8.3% were identified as likely (grade 2), and 6.3% identified as least likely (grade 1) to have an eosinophilic phenotype, and 1.6% of patients showed a noneosinophilic phenotype (grade 0). Eosinophilic phenotype patients (ie, grades 2 or 3) showed later asthma onset (29.1 years vs 6.7 years; P < .001) and worse lung function (postbronchodilator % predicted FEV1, 76.1% vs 89.3%; P = .027) than those with a noneosinophilic phenotype. Patients with noneosinophilic phenotypes were more likely to be women (81.5% vs 62.9%; P = .047), to have eczema (20.8% vs 8.5%; P = .003), and to use anti-IgE (32.1% vs 13.4%; P = .004) and leukotriene receptor antagonists (50.0% vs 28.0%; P = .011) add-on therapy. Interpretation: According to this multicomponent, consensus-driven, and evidence-based eosinophil gradient algorithm (using variables readily accessible in real life), the severe asthma eosinophilic phenotype was more prevalent than previously identified and was phenotypically distinct. This pragmatic gradient algorithm uses variables readily accessible in primary and specialist care, addressing inherent issues of phenotype heterogeneity and phenotype instability. Identification of treatable traits across phenotypes should improve therapeutic precision. publishedVersion
- Published
- 2021
33. ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19
- Author
-
Möhlendick, Birte, Schönfelder, Kristina, Breuckmann, Katharina, Elsner, Carina, Babel, Nina, Balfanz, Paul, Dahl, Edgar, Dreher, Michael, Fistera, David, Herbstreit, Frank, Hölzer, Bodo, Koch, Michael, Kohnle, Matthias, Marx, Nikolaus, Risse, Joachim, Schmidt, Karsten, Skrzypczyk, Sarah, Sutharsan, Sivagurunathan, Taube, Christian, Westhoff, Timm H, Jöckel, Karl-Heinz, Dittmer, Ulf, Siffert, Winfried, and Kribben, Andreas
- Subjects
Adult ,Male ,Adolescent ,Genotype ,rs2285666 ,Medizinische Fakultät » Universitätsklinikum Essen » Ruhrlandklinik Essen – Universitätsklinik ,viruses ,Medizin ,ACE2 ,Polymorphism, Single Nucleotide ,Severity of Illness Index ,Young Adult ,coronavirus disease 2019 ,Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Nephrologie ,Risk Factors ,Humans ,Genetic Predisposition to Disease ,ddc:610 ,skin and connective tissue diseases ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Medizinische Informatik, Biometrie und Epidemiologie ,Aged ,Aged, 80 and over ,fungi ,virus diseases ,COVID-19 ,Original Articles ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Virologie ,Middle Aged ,single-nucleotide polymorphism ,body regions ,Medizinische Fakultät » Universitätsklinikum Essen » Zentrum für Notfallmedizin ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Pharmakogenetik ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Female ,Angiotensin-Converting Enzyme 2 ,Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Anästhesiologie und Intensivmedizin ,severe acute respiratory syndrome coronavirus 2 - Abstract
Supplemental Digital Content is available in the text., Objectives The RNA virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19). Cell entry is mediated by the human angiotensin-converting enzyme II (ACE2). ACE2 and its close homolog angiotensin-converting enzyme I (ACE) are currently discussed candidate genes, in which single-nucleotide polymorphisms (SNPs) could alter binding or entry of SARS-CoV-2 and enhance tissue damage in the lung or other organs. This could increase the susceptibility for SARS-CoV-2 infection and the severity of COVID-19. Patients and methods We performed genotyping of SNPs in the genes ACE2 and ACE in 297 SARS-CoV-2-positive and 253 SARS-CoV-2-negative tested patients. We analyzed the association of the SNPs with susceptibility for SARS-CoV-2 infection and the severity of COVID-19. Results SARS-CoV-2-positive and SARS-CoV-2-negative patients did not differ regarding demographics and clinical characteristics. For ACE2 rs2285666, the GG genotype or G-allele was significantly associated with an almost two-fold increased SARS-CoV-2 infection risk and a three-fold increased risk to develop serious disease or COVID-19 fatality. In contrast, the ACE polymorphism was not related to infection risk or severity of disease. In a multivariable analysis, the ACE2 rs2285666 G-allele remained as an independent risk factor for serious disease besides the known risk factors male gender and cardiovascular disease. Conclusions In summary, our report appears to be the first showing that a common ACE2 polymorphism impacts the risk for SARS-CoV-2 infection and the course of COVID-19 independently from previously described risk factors.
- Published
- 2021
34. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma
- Author
-
Meghoufel, Z, Cherifi, F, Boukra, A, Terki, F, Porsbjerg, Celeste, Menzies-Gow, Andrew, Tran, Trung, Murray, Ruth, Unni, Bindhu, Audrey Ang, Shi Ling, Alacqua, Marianna, Al-Ahmad, Mona, Al-Lehebi, Riyad, Altraja, Alan, Belevskiy, Andrey, Björnsdóttir, Unnur, Bourdin, Arnaud, Busby, John, Canonica, G. Walter, Christoff, George, Cosio, Borja, Costello, Richard, FitzGerald, J. Mark, Fonseca, João, Hansen, Susanne, Heaney, Liam, Heffler, Enrico, Hew, Mark, Iwanaga, Takashi, Jackson, David, Kocks, Janwillem W.H., Kallieri, Maria, Bruce Ko, Hsin-Kuo, Koh, Mariko Siyue, Larenas-Linnemann, Désirée, Lehtimäki, Lauri, Loukides, Stelios, Lugogo, Njira, Maspero, Jorge, Papaioannou, Andriana, Perez-de-Llano, Luis, Pitrez, Paulo Márcio, Popov, Todor, Rasmussen, Linda, Rhee, Chin Kook, Sadatsafavi, Mohsen, Schmid, Johannes, Siddiqui, Salman, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos, Ulrik, Charlotte, Upham, John, Wang, Eileen, Wechsler, Michael, Bulathsinhala, Lakmini, Carter, Victoria, Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Rowlands, Mari-Anne, Price, David, van Boven, Job FM., Groningen Research Institute for Asthma and COPD (GRIAC), Value, Affordability and Sustainability (VALUE), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Subjects
Severe asthma ,Biological Products ,[SDV]Life Sciences [q-bio] ,Medizin ,Biologics access ,Omalizumab ,3. Good health ,Biologics eligibility ,Biological Therapy ,03 medical and health sciences ,BIOLOGICS ,0302 clinical medicine ,Prescriptions ,030228 respiratory system ,Immunology and Allergy ,Humans ,ASTHMA ,030212 general & internal medicine ,Anti-Asthmatic Agents ,ComputingMilieux_MISCELLANEOUS ,SEVERE ASTHMA - Abstract
BackgroundRegulatory bodies have approved five biologics for severe asthma. However, regional differences in accessibility may limit the global potential for personalized medicine.ObjectiveTo compare global differences in ease of access to biologics.MethodsIn April 2021, national prescription criteria for omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab were reviewed by severe asthma experts collaborating in the International Severe Asthma Registry. Outcomes (per country, per biologic) were (1) country-specific prescription criteria and (2) development of the Biologic Accessibility Score (BACS). The BACS composite score incorporates 10 prescription criteria, each with a maximum score of 10 points. Referenced to European Medicines Agency marketing authorization specifications, a higher score reflects easier access.ResultsBiologic prescription criteria differed substantially across 28 countries from five continents. Blood eosinophil count thresholds (usually ≥300 cells/μL) and exacerbations were key requirements for anti-IgE/anti–IL-5/5R prescriptions in around 80% of licensed countries. Most countries (40% for dupilumab to 54% for mepolizumab) require two or more moderate or severe exacerbations, whereas numbers ranged from none to four. Moreover, 0% (for reslizumab) to 21% (for omalizumab) of countries required long-term oral corticosteroid use. The BACS highlighted marked between-country differences in ease of access. For omalizumab, mepolizumab, benralizumab, and dupilumab, only two, one, four, and seven countries, respectively, scored equal or higher than the European Medicines Agency reference BACS. For reslizumab, all countries scored lower.ConclusionsAlthough some differences were expected in country-specific biologic prescription criteria and ease of access, the substantial differences found in the current study present a challenge to implementing precision medicine across the world.
- Published
- 2022
35. Transmembrane serine protease 2 Polymorphisms and Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection: a German Case-Control Study
- Author
-
Schönfelder, Kristina, Breuckmann, Katharina, Elsner, Carina, Dittmer, Ulf, Fistera, David, Herbstreit, Frank, Risse, Joachim, Schmidt, Karsten-Daniel, Sutharsan, Sivagurunathan, Taube, Christian, Jöckel, Karl-Heinz, Siffert, Winfried, Kribben, Andreas, and Möhlendick, Birte
- Subjects
rs12329760 ,genetic association ,viruses ,Medizinische Fakultät » Universitätsklinikum Essen » Ruhrlandklinik Essen – Universitätsklinik ,fungi ,Medizin ,rs2070788 ,virus diseases ,rs383510 ,Brief Research Report ,QH426-470 ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Virologie ,polymorphism ,body regions ,transmembrane serine protease 2 ,coronavirus disease 2019 ,Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Nephrologie ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Pharmakogenetik ,Genetics ,ddc:610 ,severe acute respiratory syndrome coronavirus type 2 ,skin and connective tissue diseases ,Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Anästhesiologie und Intensivmedizin ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Medizinische Informatik, Biometrie und Epidemiologie - Abstract
The transmembrane serine protease 2 (TMPRSS2) is the major host protease that enables entry of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) into host cells by spike (S) protein priming. Single nucleotide polymorphisms (SNPs) in the gene TMPRSS2 have been associated with susceptibility to and severity of H1N1 or H1N9 influenza A virus infections. Functional variants may influence SARS-CoV-2 infection risk and severity of Coronavirus disease 2019 (COVID-19) as well. Therefore, we analyzed the role of SNPs in the gene TMPRSS2 in a German case-control study. We performed genotyping of the SNPs rs2070788, rs383510, and rs12329760 in the gene TMPRSS2 in 239 SARS-CoV-2-positive and 253 SARS-CoV-2-negative patients. We analyzed the association of the SNPs with susceptibility to SARS-CoV-2 infection and severity of COVID-19. SARS-CoV-2-positive and SARS-CoV-2-negative patients did not differ regarding their demographics. The CC genotype of TMPRSS2 rs383510 was associated with a 1.73-fold increased SARS-CoV-2 infection risk, but was not correlated to severity of COVID-19. Neither TMPRSS2 rs2070788 nor rs12329760 polymorphisms were related to SARS-CoV-2 infection risk or severity of COVID-19. In a multivariable analysis (MVA), the rs383510 CC genotype remained an independent predictor for a 2-fold increased SARS-CoV-2 infection risk. In summary, our report appears to be the first showing that the intron variant rs383510 in the gene TMPRSS2 is associated with an increased risk to SARS-CoV-2 infection in a German cohort. OA Förderung 2021
- Published
- 2021
36. Potential Prognostic Value of Preoperative Leukocyte Count, Lactate Dehydrogenase and C-Reactive Protein in Thymic Epithelial Tumors
- Author
-
Valdivia, Daniel, Cheufou, Danjouma, Fels, Benjamin, Puhlvers, Stephan, Mardanzai, Khaled, Zaatar, Mohamed, Weinreich, Gerhard, Taube, Christian, Theegarten, Dirk, Stuschke, Martin, Schuler, Martin, Stamatis, Georgios, Hegedus, Balazs, and Aigner, Clemens
- Subjects
Medizinische Fakultät » Universitätsklinikum Essen » Innere Klinik (Tumorforschung) ,Cancer Research ,LDH ,Medizinische Fakultät » Universitätsklinikum Essen » Ruhrlandklinik Essen – Universitätsklinik ,Medizin ,General Medicine ,thymoma ,Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Strahlentherapie ,Medizinische Fakultät » Universitätsklinikum Essen » Westdeutsches Tumorzentrum Essen (WTZ) ,C-reactive protein ,Pathology and Forensic Medicine ,Oncology ,thymic epithelial tumor ,ddc:610 ,CRP ,thymectomy - Abstract
Thymic epithelial tumors are the most common mediastinal tumors. Surgery is the mainstay of treatment and complete resection provides the best survival rate. However, advanced tumors often require multimodality treatment and thus we analyzed the prognostic potential of routine circulating biomarkers that might help to risk-stratify patients beyond tumor stage and histology. Preoperative values for white blood cell count (WBC), C-reactive protein (CRP) and lactate dehydrogenase (LDH) were analyzed in 220 thymic epithelial tumor patients operated between 1999 and 2018. Increased CRP levels (>1 mg/dl) were significantly more often measured in thymic carcinoma and neuroendocrine tumors when compared to thymoma. LDH serum activity was higher in thymic neuroendocrine tumors when compared to thymoma or thymic carcinoma. The median disease specific survival was significantly longer in thymoma cases than in thymic carcinoma and neuroendocrine tumors. Increased preoperative LDH level (>240 U/L) associated with shorter survival in thymus carcinoma (HR 4.76, p = 0.0299). In summary, higher CRP associated with carcinoma and neuroendocrine tumors, while LDH increased primarily in neuroendocrine tumors suggesting that biomarker analysis should be performed in a histology specific manner. Importantly, preoperative serum LDH might be a prognosticator in thymic carcinoma and may help to risk stratify surgically treated patients in multimodal treatment regimens. OA Förderung 2021
- Published
- 2021
- Full Text
- View/download PDF
37. S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma - Addendum 2020 : herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. und der Deutschen Atemwegsliga e.V., unter Beteiligung der Gesellschaft für Pädiatrische Pneumologie e.V. und der Österreichischen Gesellschaft für Pneumologie
- Author
-
Buhl, R., Bals, R., Baur, X., Berdel, D., Criée, C.-P., Gappa, M., Gillissen, A., Greulich, T., Haidl, P., Hamelmann, E., Horak, F., Kardos, P., Kenn, K., Klimek, L., Korn, S., Magnussen, H., Nowak, D., Pfaar, O., Rabe, K.F., Riedler, J., Ritz, T., Schultz, K., Schuster, A., Spindler, T., Taube, Christian, Vogelmeier, C., Von Leupoldt, A., Wantke, F., Wildhaber, J., Worth, H., Zacharasiewicz, A., and Lommatzsch, M.
- Subjects
Adult ,Adolescent ,immune system diseases ,Austria ,Medizin ,Pulmonary Medicine ,Humans ,Child ,Asthma ,Societies, Medical ,respiratory tract diseases - Abstract
The present addendum of the guideline for the diagnosis and treatment of asthma (2017) complements new insights into the diagnosis and management of asthma as well as for the newly approved drugs for the treatment of asthma. Current, evidence-based recommendations on diagnostic and therapeutic approaches are presented for children and adolescents as well as for adults with asthma.Das vorliegende Addendum zur Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma (2017) ergänzt wichtige neue Erkenntnisse zur Diagnostik und Therapie von Asthma sowie zu neu für die Therapie des Asthmas zugelassenen Medikamenten. Es werden sowohl für Kinder und Jugendliche als auch für Erwachsene mit Asthma die aktuellen, Evidenz-basierten diagnostischen und therapeutischen Empfehlungen dargelegt.
- Published
- 2021
38. Seasonality of Non-SARS, Non-MERS Coronaviruses and the Impact of Meteorological Factors
- Author
-
Anastasiou, Olympia E., Hüsing, Anika, Korth, Johannes, Theodoropoulos, Fotis, Taube, Christian, Jöckel, Karl-Heinz, Stang, Andreas, and Dittmer, Ulf
- Subjects
immunosuppression ,seasonality ,Medizinische Fakultät » Universitätsklinikum Essen » Ruhrlandklinik Essen – Universitätsklinik ,lcsh:R ,Medizin ,coronavirus ,meteorological ,lcsh:Medicine ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Virologie ,Article ,Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Nephrologie ,weather ,ddc:610 ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Medizinische Informatik, Biometrie und Epidemiologie - Abstract
Background: Seasonality is a characteristic of some respiratory viruses. The aim of our study was to evaluate the seasonality and the potential effects of different meteorological factors on the detection rate of the non-SARS coronavirus detection by PCR. Methods: We performed a retrospective analysis of 12,763 respiratory tract sample results (288 positive and 12,475 negative) for non-SARS, non-MERS coronaviruses (NL63, 229E, OC43, HKU1). The effect of seven single weather factors on the coronavirus detection rate was fitted in a logistic regression model with and without adjusting for other weather factors. Results: Coronavirus infections followed a seasonal pattern peaking from December to March and plunged from July to September. The seasonal effect was less pronounced in immunosuppressed patients compared to immunocompetent patients. Different automatic variable selection processes agreed on selecting the predictors temperature, relative humidity, cloud cover and precipitation as remaining predictors in the multivariable logistic regression model, including all weather factors, with low ambient temperature, low relative humidity, high cloud cover and high precipitation being linked to increased coronavirus detection rates. Conclusions: Coronavirus infections followed a seasonal pattern, which was more pronounced in immunocompetent patients compared to immunosuppressed patients. Several meteorological factors were associated with the coronavirus detection rate. However, when mutually adjusting for all weather factors, only temperature, relative humidity, precipitation and cloud cover contributed independently to predicting the coronavirus detection rate. OA Förderung 2021
- Published
- 2021
39. Bilateral Lung Transplantation due to non-specific interstitial Pneumonia (NSIP) after SARS-CoV2 Pneumonia in Patients with Crohn's Disease
- Author
-
Theegarten, Dirk, Besa, Vasiliki, Witzke, Oliver, Brenner, Thorsten, Taube, Christian, Aigner, Clemens, and Kamler, Markus
- Subjects
Medizin - Published
- 2021
40. Pulmonale Manifestation einer extragenitalen Endometriose
- Author
-
Knoop, Heiko, Krolzig, S., Knoop, Umut, and Taube, Christian
- Subjects
Medizin - Published
- 2021
41. Biologika bei atopischen Erkrankungen : Indikationsstellung, Nebenwirkungsmanagement und neue Entwicklungen
- Author
-
Jappe, Uta, Beckert, Hendrik, Bergmann, Karl Christian, Gülşen, Aşkın, Klimek, Ludger, Philipp, Sandra, Pickert, Julia, Rauber-Ellinghaus, M., Renz, Harald E., Taube, Christian, Treudler, Regina, Wagenmann, Martin M., Werfel, Thomas, Worm, Margitta M., and Zuberbier, Thorsten
- Subjects
Gynecology ,medicine.medical_specialty ,Immune status ,Diagnostic methods ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Chronic rhinosinusitis ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Medizin ,Atopic dermatitis ,medicine.disease ,medicine ,Immunology and Allergy ,Disease characteristics ,business ,Asthma - Abstract
Mit den Biologika stehen zunehmend mehr Therapeutika zur Verfugung, die zielgerichtet bestimmte Schaltstellen im Pathomechanismus immunologisch dominierter Erkrankungen adressieren Damit steht mehr die individuelle Krankheitsauspragung des einzelnen Patienten im Fokus der Diagnostik und Therapie (Prazisionsmedizin) Bezuglich der unterschiedlichen Phanotypen atopischer Erkrankungen war das schwere Asthma die erste Entitat, fur die Biologika zugelassen wurde, gefolgt von Urtikaria, und schlieslich der atopischen Dermatitis und der chronischen Rhinosinusitis mit nasalen Polypen Die Erfahrungen in der Therapie des schweren Asthma bronchiale machten deutlich, dass die Intensitat des Ansprechens auf eine Biologikatherapie entscheidend von der Qualitat der klinischen und immunologischen Phanotypisierung der Patienten abhangt, wobei diese Unterscheidung z T schwierig sein kann und sich verschiedene Phanotypen durchaus uberlagern konnen Das gilt auch fur unterschiedliche Erkrankungen des atopischen Formenkreises, da Patienten in jeweils entsprechend unterschiedlicher Auspragung unter mehreren atopischen Krankheiten gleichzeitig leiden konnen Es bilden sich bereits Biologika heraus, die eine geeignete Therapie fur das allergische Asthma bronchiale, das haufig gemeinsam mit einer schweren Neurodermitis auftritt, sowie die chronische Rhinosinusitis mit nasalen Polypen darstellen konnen In der Praxis stellt sich dennoch zunehmend die Frage nach moglichen Biologika-Kombinationen zur Therapie komplexer Krankheitsbilder einzelner Patienten Dabei gilt es, das Nebenwirkungsprofil zu beachten, zu denen auch Hypersensitivitatsreaktionen gehoren, deren diagnostisches und logistisches Management eine sichere und effiziente Therapie der Grunderkrankung zum Ziel haben muss Erhohte Aufmerksamkeit gilt auch fur eine Biologikatherapie bei Schwangerschaften und geplanten (planbaren) Impfungen sowie bestehenden Infektionen, wie zum Beispiel die SARS-CoV-2-Infektion Vor dem Start einer Biologikatherapie sollten der Immunstatus in Bezug auf chronische Virusund bakterielle Infektionen gepruft und gegebenenfalls vor Therapieeinleitung der Impfstatus aufgefrischt bzw fehlende Impfungen nachgeholt werden Derzeit liegen verlassliche Daten zum Effekt von Biologika auf die immunologische Situation der SARS-CoV-2-Infektion und COVID-19 nicht vor Daher ist die Erforschung und Entwicklung geeigneter Diagnostikverfahren zur Erfassung immunologisch bedingter Nebenwirkungen sowie der Erfassung potenzieller Therapie-Responder und -Non-Responder von groser BedeutungAlternate abstract:With the advent of biologicals, more and more therapeutics are available that specifically address specific switch points in the pathomechanism of immunologically dominated diseases Thus, the focus of diagnostics and therapy (precision medicine) is more on the individual disease characteristics of the individual patient Regarding the different phenotypes of atopic diseases, severe asthma was the first entity for which biologicals were approved, followed by urticaria, and finally atopic dermatitis and chronic rhinosinusitis with nasal polyps Experience in the treatment of severe bronchial asthma has shown that the intensity of the response to biological therapy depends on the quality of clinical and immunological phenotyping of the patients This also applies to different diseases of the atopic form, as patients can suffer from several atopic diseases at the same time, each with different characteristics Biologics are already emerging that may represent a suitable therapy for allergic bronchial asthma, which often occurs together with severe neurodermatitis, and chronic rhinosinusitis with nasal polyps In practice, however, the question of possible combinations of biologicals for the therapy of complex clinical pictures of individual patients is increasingly arising In doing so, the side effect profile must be taken into account, including hypersensitivity reactions, whose diagnostic and logistical management must aim at a safe and e ficient therapy of the underlying disease Increased attention must also be paid to biological therapy in pregnancy and planned (predictable) vaccinations as well as existing infections, such as SARS-CoV-2 infection Before starting a biological therapy, the immune status should be checked with regard to chronic viral and bacterial infections and, if necessary, the vaccination status should be refreshed or missing vaccinations should be made up for before starting therapy Currently, reliable data on the effect of biologicals on the immunological situation of SARS-CoV-2 infection and COVID-19 are not available Therefore, research and development of suitable diagnostic methods for detection of immunologically caused side effects as well as detection of potential therapy responders and non-responders is of great importance
- Published
- 2021
42. COVID-19 Vaccination in Asthma Patients Treated with Biologicals : Statement of the Austrian Society of Pneumology and German Respiratory Society
- Author
-
Idzko, M., Buhl, R., Eber, E., Hamelmann, E., Lamprecht, B., Horak, F., Pohl, W., and Taube, Christian
- Subjects
Medizin - Published
- 2021
43. COVID-19 Vaccination of Allergic Patients in Conjunction with allergen immunotherapy (AIT) : A position paper of the Association of German Allergists (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI)
- Author
-
Klimek, Ludger, Pfaar, Oliver, Hamelmann, E., Kleine-Tebbe, Jörg, Taube, Christian, Wagenmann, Martin, Werfel, Thomas, Brehler, Randolph, Novak, Natalija, Mülleneisen, Norbert, Becker, Sven, and Worm, Margitta
- Subjects
Medizin - Published
- 2021
44. Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie : Ein Positionspapier von ARIA, EAACI, AeDA, GPA und DGAKI (Kurzversion)
- Author
-
Pfaar, O., Klimek, L., Worm, M., Bergmann, K.-C., Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Mösges, R., Saloga, J., Staubach, P., Stute, P., Rabe, K., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P.-V., Aberer, W., Fink-Wagner, A., Horak, F., Wöhrl, S., Niederberger-Leppin, V., Pali-Schöll, I., Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Akdis, C., Hoffmann-Sommergruber, K., Jutel, M., Matricardi, P., Spertini, F., Khaltaev, N., Michel, J.-P., Nicod, L., Schmid-Grendelmeier, P., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, Christian, Gerstlauer, M., Vogelberg, C., Bousquet, J., and Zuberbier, T.
- Subjects
Betacoronavirus ,Desensitization, Immunologic ,SARS-CoV-2 ,Pneumonia, Viral ,Medizin ,COVID-19 ,Humans ,Coronavirus Infections ,Pandemics - Published
- 2020
45. Predictive value of Chartis measurement for lung function improvements in bronchoscopic lung volume reduction
- Author
-
Wienker, Johannes, Karpf-Wissel, Rüdiger, Funke, Faustina, Taube, Christian, Wälscher, Julia, Winantea, Jane, Maier, Sandra, Mardanzai, Khaled, and Darwiche, Kaid
- Subjects
Male ,Medizinische Fakultät » Universitätsklinikum Essen » Ruhrlandklinik Essen – Universitätsklinik ,Vital Capacity ,Medizin ,bronchoscopic lung volume reduction ,Pulmonary Disease, Chronic Obstructive ,collateral ventilation ,Forced Expiratory Volume ,Bronchoscopy ,Humans ,ddc:610 ,Lung ,Original Research ,Aged ,Retrospective Studies ,lcsh:RC705-779 ,Chartis ,Recovery of Function ,lcsh:Diseases of the respiratory system ,Middle Aged ,emphysema ,Treatment Outcome ,Pulmonary Emphysema ,Medizinische Fakultät » Universitätsklinikum Essen » Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie ,Female ,Lung Volume Measurements - Abstract
Background: Bronchoscopic lung volume reduction (BLVR) via valve implantation can be achieved by targeting severely hyperinflated and emphysematously destructed lung areas in patients with chronic obstructive lung disease. Lack of collateral ventilation (CV) is important for good outcomes with BLVR. CV can be measured using the catheter-based Chartis system. The aim of this study was to evaluate the correlation between total exhaled volume drained from the target lobe measured by Chartis and clinical outcomes after BLVR in CV-negative patients. Methods: From January 2016 to March 2019, 60 patients were included in this retrospective single-center analysis. Drained volume (TVol) measured by Chartis was recorded and compared with lung function and physical performance parameters. Outcome variables included the percentage change in lung function [forced expiratory volume in 1 s (FEV 1 ), residual volume (RV), and inspiratory vital capacity (IVC)]. Secondary outcomes were the degree of target lobe volume reduction (TLVR), change in 6-min walk distance (6MWD), and change in chronic obstructive pulmonary disease (COPD) assessment test (CAT) score. Results: Drained volume correlated significantly with post-BLVR change in FEV 1 ( r = 0.663), IVC ( r = 0.611), RV ( r = −0.368), and TLVR ( r = 0.635) (all p 400 ml ( n = 8)]; mean changes in FEV 1 were 2.6%, 17.4%, and 51.3%; in RV were −3.9%, −10.6%, and −23.8%; in IVC were −4.0%, 10.6%, and 62.4%; and in TLVR were 525 ml (39%), 1375 ml (73%) and 1760 ml (100%), respectively. There were no significant correlations between absolute and percentage changes in 6MWD and the CAT score. Lung volume reduction was diagnosed in 32 (53%) cases. Conclusion: Drained volume measured by the Chartis system correlated with functional improvement in CV-negative patients undergoing BLVR. The reviews of this paper are available via the supplemental material section.
- Published
- 2020
46. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET
- Author
-
Kirsten Anne-Marie, Anne Wirz, Erich Traugott, Ficker Joachim H, Bertram J. Jobst, Vivien Janke, Stubbe Beate, Johanna I. Lutter, Barbara Ziss, Franziska C. Trudzinski, Patricia Berger, Henrik Watz, Gogol Manfred, Thomas Bahmer, Beate Polte, Kronsbein Juliane, Campus Kiel, Lange Christoph, Martina Seibert, Rudolf A. Jörres, Pfeifer Michael, Timmermann Hartmut, Grohé Christian, Tobias Welte, Studnicka Michael, Petra Hundack-Winter, Jana Graf, Jürgen Behr, Diana Schottel, Buhl Roland, Virchow J. Christian, Bewig Burkhard, Ruhrlandklinik gGmbH. Essen, Wirtz Hubert, Rosalie Untsch, Birte Struck, Peter Alter, Kathrin Kahnert, Gudrun Hübner, Vogelmeier Claus, Sabine Michalewski, Kropf-Sanchen Cornelia, Kenn Klaus, Pontus Mertsch, Sonja Rohweder, Hauck Rainer, Andreas Stefan, Ilona Kietzmann, Zabel Peter, Michaela Schrade-Illmann, Höffken Gerd, Julia Tobias, Frank Biertz, Seeger Werner, Manuel Klöser, Kahnert Kathrin, Teschler Helmut, Anita Reichel, Gina Spangel, Ulrike Rieber, Randerath Winfried J, Julia Teng, Tanja Lucke, Herth Felix, Jeanette Pieper, Lenka Krabbe, Taube Christian, Jürgen Biederer, Wagner Ulrich, Doris Lehnert, Claus Vogelmeier, Katrin Schwedler, Henke Markus, Jany Berthold, Katus Hugo A, Bals Robert, Zaklina Hinz, Cornelia Böckmann, Ellen Burmann, Margret Gleiniger, Behr Jürgen, Britta Markworth, Ewert Ralf, Gertraud Weiß, Katrin Wons, Barbara Arikan, Watz Henrik, Beate Schaufler, Lena Sterk, Robert Bals, Hans-Ulrich Kauczor, Koczulla Rembert, Held Matthias, and Welte Tobias
- Subjects
Pulmonary and Respiratory Medicine ,Male ,medicine.medical_specialty ,Copd patients ,Medizin ,Comorbidity ,Severity of Illness Index ,Pulmonary Disease, Chronic Obstructive ,Medicine ,Humans ,In patient ,Lung ,Aged ,Aged, 80 and over ,COPD ,Bronchiectasis ,business.industry ,Phlegm ,Middle Aged ,medicine.disease ,Radiological weapon ,Clinical diagnosis ,Cohort ,Female ,Radiography, Thoracic ,Radiology ,medicine.symptom ,business ,Tomography, X-Ray Computed - Abstract
Bronchiectasis (BE) might be frequently present in COPD but masked by COPD symptoms. We studied the relationship of clinical signs of bronchiectasis to the presence and extent of its radiological signs in patients of different COPD severity. Visit 4 data (GOLD grades 1-4) of the COSYCONET cohort was used. Chest CT scans were evaluated for bronchiectasis in 6 lobes using a 3-point scale (0: absence, 1: ≤50%, 2: >50% BE-involvement for each lobe). 1176 patients were included (61%male, age 67.3y), among them 38 (3.2%) with reported physicians' diagnosis of bronchiectasis and 76 (6.5%) with alpha1-antitrypsin deficiency (AA1D). CT scans were obtained in 429 patients. Within this group, any signs of bronchiectasis were found in 46.6% of patients, whereby ≤50% BE occurred in 18.6% in ≤2 lobes, in 10.0% in 3-4 lobes, in 15.9% in 5-6 lobes; >50% bronchiectasis in at least 1 lobe was observed in 2.1%. Scores ≥4 correlated with an elevated ratio FRC/RV. The clinical diagnosis of bronchiectasis correlated with phlegm and cough and with radiological scores of at least 3, optimally ≥5. In COPD patients, clinical diagnosis and radiological signs of BE showed only weak correlations. Correlations became significant with increasing BE-severity implying radiological alterations in several lobes. This indicates the importance of reporting both presence and extent of bronchiectasis on CT. Further research is warranted to refine the criteria for CT scoring of bronchiectasis and to determine the relevance of radiologically but not clinically detectible bronchiectasis and their possible implications for therapy in COPD patients.
- Published
- 2020
47. CAT score single item analysis in patients with COPD: results from COSYCONET
- Author
-
J. Randerath Winfried, Pfeifer Michael, Kenn Klaus, Joachim H. Ficker, Gogol Manfred, Grohé Christian, Höffken Gerd, Zaklina Hinz, Julia Tobias, Henke Markus, Teschler Helmut, Welte Tobias, Benjamin Waschki, Buhl Roland, Paul W. Jones, Kirsten Anne-Marie, A. Katus Hugo, Taube Christian, Bewig Burkhard, Beate Polte, Kronsbein Juliane, Stubbe Beate, Bals Robert, Johanna I. Lutter, Sarah Marietta von Siemens, Lange Christoph, Vogelmeier Claus, Ellen Burmann, Wirtz Hubert, Kathrin Kahnert, Erich Traugott, Behr Jürgen, Birte Struck, Vivien Janke, Lenka Krabbe, Timmermann Hartmut, Wagner Ulrich, Anita Reichel, Sabine Michalewski, Gudrun Hübner, Seeger Werner, Doris Lehnert, Jany Berthold, Kropf-Sanchen Cornelia, Sandra Söhler, Jeanette Pieper, Ulrike Rieber, Peter Alter, Herth Felix, Zabel Peter, Andreas Stefan, Koczulla Rembert, Held Matthias, Tobias Welte, Franziska C. Trudzinski, Patricia Berger, Kahnert Kathrin, Jana Graf, Jürgen Behr, Rosalie Untsch, Rudolf A. Jörres, Kornelia Speth, Britta Markworth, Ewert Ralf, Gertraud Weiß, Hans-Ulrich Kauczor, Claus Vogelmeier, Katrin Schwedler, Katrin Wons, Bertram J. Jobst, Barbara Arikan, Margret Gleiniger, Henrik Watz, Watz Henrik, Studnicka Michael, Beate Schaufler, Diana Schottel, Sonja Rohweder, Robert Bals, Ilona Kietzmann, Virchow J. Christian, Burkhard Bewig, Hauck Rainer, and Michaela Schrade-Illmann
- Subjects
Pulmonary and Respiratory Medicine ,Percentile ,medicine.medical_specialty ,Medizin ,Diagnostic Techniques, Respiratory System ,Single item ,CAT score ,03 medical and health sciences ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Internal medicine ,medicine ,COPD ,In patient ,030212 general & internal medicine ,Lung function ,Emphysema ,business.industry ,Regression analysis ,Cat Score ,Copd ,medicine.disease ,Exploratory factor analysis ,respiratory tract diseases ,030228 respiratory system ,Cohort ,business - Abstract
The COPD Assessment Test (CAT) is in widespread use for the evaluation of patients with chronic obstructive pulmonary disease (COPD). We assessed whether the CAT items carry additional information beyond the sum score regarding COPD characteristics including emphysema. Patients of GOLD grades 1 to 4 from the COPD cohort COSYCONET (German COPD and Systemic Consequences - Comorbidities Network) with complete CAT data were included (n = 2270), of whom 493 had chest CT evaluated for the presence of emphysema. Comorbidities and lung function were assessed following standardised procedures. Cross-sectional data analysis was based on multiple regression analysis of the single CAT items against a panel of comorbidities, lung function, or CT characteristics (qualitative score, 15th percentile of mean lung density), with age, BMI and gender as covariates. This was supported by exploratory factor analysis. Regarding the relationship to comorbidities and emphysema, there were marked differences between CAT items, especially items 1 and 2 versus 3 to 8. This grouping was basically confirmed by factor analysis. Items 4 and 5, and to a lower degree 1, 2 and 6, appeared to be informative regarding the presence of emphysema, whereas the total score was not or less informative. Regarding comorbidities, similar findings as for the total CAT score were obtained for the modified Medical Research Council scale (mMRC) which was also informative regarding emphysema. Our findings suggest that the usefulness of the CAT can be increased if evaluated on the basis of single items which may be indicating the presence of comorbidities and emphysema.
- Published
- 2020
48. Fallbericht: Bridging to Recovery mittels ECMO-Therapie bei E-Zigaretten-assoziiertem Lungenschaden (EVALI) bei einem 19-jährigen Patienten
- Author
-
Herbstreit, Frank, Welsner, M., Taube, Christian, Ernst, E.-C., Stöppler, T., Brenner, Thorsten, and Schmidt, Karsten-Daniel
- Subjects
Medizin - Published
- 2020
49. COVID-19 Triage : Who is an inpatient? The Essen triage model
- Author
-
Fistera, David, Risse, Joachim, Manegold, Randi Katrin, Pabst, Dirk, Konik, Margarete, Dolff, Sebastian, Witzke, Oliver, Schaarschmidt, Benedikt Michael, Taube, Christian, Kill, Clemens, and Holzner, Carola
- Subjects
Medizin - Published
- 2020
50. Use of biologicals in allergic and type 2 inflammatory diseases in the current COVID-19 pandemic
- Author
-
Taube, Christian
- Subjects
Medizin - Abstract
Weitere Nicht-UDE-Autoren sind nicht genannt.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.